at-13387 and Prostatic-Neoplasms

at-13387 has been researched along with Prostatic-Neoplasms* in 2 studies

Reviews

1 review(s) available for at-13387 and Prostatic-Neoplasms

ArticleYear
Role of androgen receptor splice variants, their clinical relevance and treatment options.
    World journal of urology, 2020, Volume: 38, Issue:3

    In this review, we summarize the importance of AR variants with a particular focus on clinically relevant members of this family.. A non-systematic literature review was performed based on Medline and PubMed.. Endocrine therapy represents the central paradigm for the management of prostate cancer. Eventually, in response to androgen ablation therapy, several resistance mechanisms against the endocrine therapy might develop that can circumvent the therapy approaches. One specific resistance mechanism that has gained increasing attention is the generation of alternatively spliced variants of the androgen receptor, with AR-V7 being the most prominent. More broadly, AR-V7 is one member of a group of alternatively spliced AR variants that share a common feature, the missing ligand-binding domain. These ΔLBD androgen receptor variants have shown the capability to induce androgen receptor-mediated gene transcription even under conditions of androgen deprivation and to drive cancer progression.. The methods used for detecting AR-Vs, at least on the mRNA level, are well-advanced and harbor the potential to be introduced into clinical diagnostics. It is important to note, that the testing, especially of AR-V7 has its limitations in predicting treatment response. More promising is the great number of active clinical trials aimed at reducing the AR-Vs, and using this to re-sensitize CRPC towards endocrine treatment might provide additional treatment options for CRPC patients in the future.

    Topics: Alternative Splicing; Androgen Antagonists; Androstadienes; Antineoplastic Agents, Hormonal; Benzamides; Benzhydryl Compounds; Benzimidazoles; Benzoquinones; Binding Sites; Chlorohydrins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Isoindoles; Isoxazoles; Lactams, Macrocyclic; Male; Niclosamide; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Domains; Protein Isoforms; Proteins; Receptors, Androgen; Resorcinols; RNA, Messenger

2020

Other Studies

1 other study(ies) available for at-13387 and Prostatic-Neoplasms

ArticleYear
Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.
    Cancer research, 2016, 05-01, Volume: 76, Issue:9

    Resistance to available hormone therapies in prostate cancer has been associated with alternative splicing of androgen receptor (AR) and specifically, the expression of truncated and constitutively active AR variant 7 (AR-V7). The transcriptional activity of steroid receptors, including AR, is dependent on interactions with the HSP90 chaperone machinery, but it is unclear whether HSP90 modulates the activity or expression of AR variants. Here, we investigated the effects of HSP90 inhibition on AR-V7 in prostate cancer cell lines endogenously expressing this variant. We demonstrate that AR-V7 and full-length AR (AR-FL) were depleted upon inhibition of HSP90. However, the mechanisms underlying AR-V7 depletion differed from those for AR-FL. Whereas HSP90 inhibition destabilized AR-FL and induced its proteasomal degradation, AR-V7 protein exhibited higher stability than AR-FL and did not require HSP90 chaperone activity. Instead, HSP90 inhibition resulted in the reduction of AR-V7 mRNA levels but did not affect total AR transcript levels, indicating that HSP90 inhibition disrupted AR-V7 splicing. Bioinformatic analyses of transcriptome-wide RNA sequencing data confirmed that the second-generation HSP90 inhibitor onalespib altered the splicing of at least 557 genes in prostate cancer cells, including AR. These findings indicate that the effects of HSP90 inhibition on mRNA splicing may prove beneficial in prostate cancers expressing AR-V7, supporting further clinical investigation of HSP90 inhibitors in malignancies no longer responsive to androgen deprivation. Cancer Res; 76(9); 2731-42. ©2016 AACR.

    Topics: Animals; Benzamides; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Immunohistochemistry; Immunoprecipitation; Isoindoles; Male; Mice; Polymerase Chain Reaction; Prostatic Neoplasms; Receptors, Androgen; RNA Splicing; RNA, Messenger; Xenograft Model Antitumor Assays

2016